Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Seres Therapeutics Inc (MCRB) USD0.001

Sell:$7.14 Buy:$7.16 Change: $0.22 (3.17%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
Change: $0.22 (3.17%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
Change: $0.22 (3.17%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis and SER-155 to treat enteric bacterial pathogens.

Contact details

200 Sidney St
United States
+1 (617) 9459626

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$636.53 million
Shares in issue:
91.72 million
United States
US dollar

Key personnel

  • Stephen Berenson
    Independent Chairman of the Board
  • Eric Shaff
    President, Chief Executive Officer, Director
  • David Arkowitz
    Chief Financial Officer, Executive Vice President, Head of Business Development
  • John Aunins
    Executive Vice President - Bioprocess and Manufacturing, Chief Technology Officer
  • David Ege
    Executive Vice President, Chief Technology Officer
  • Matthew Henn
    Executive Vice President, Chief Scientific Officer
  • Thomas DesRosier
    Chief Legal Officer, Executive Vice President , Secretary
  • Lisa von Moltke
    Executive Vice President, Chief Medical Officer
  • Teresa Young
    Executive Vice President, Chief Commercial and Strategy Officer
  • Marcus Chapman
    Senior Vice President - Finance and Principal Financial and Accounting Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.